Bone metastases are devastating developments of cancers that originate in other organs. In the case of metastatic prostate cancer, bone metastases represent an incurable, painful, and often deadly development, killing more than 30,000 American men every year. Unlike many other tumor types, metastatic prostate cancer responds poorly to immune-based therapies, but a new study published in Cancer Cell and originating in part from Harvard Stem Cell Institute (HSCI) labs, has uncovered a key mechanism for why such therapies fail to work, potentially leading the way to a breakthrough in the treatment of this devastating disease.... Read more about A new study illuminates the therapy resistance of metastatic prostate cancer
HSCI co-director David Scadden is part of a multi-institutional, cross-disciplinary team that has been awarded a $14.6 million grant from the National Institutes of Health. The team is using gene and cell therapy approaches to develop a potential cure for HIV.
The researchers will combine gene editing against HIV with technologies for safer and more effective blood stem cell transplants. Such transplants, also known as bone marrow transplants, are currently used for severe blood cancers. They renew a patient’s immune system, which can be damaged by cancer therapies, by...
The Harvard Stem Cell Institute (HSCI) was launched in 2004 with the express goal of pursuing the promise of stem cell science. In April 2019 we celebrate our 15th anniversary, and reflect on how far we have come.
Collaboration across Harvard
Our founding document listed 28 participating Harvard faculty, including co-founders Doug Melton and David Scadden. By May 2004 that list had expanded to 39 faculty, and in 2005 the number had almost doubled.